Mustang Bio (Nasdaq : MBIO ) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. [1] [2] [3] Operating as a partner company of Fortress Biotech , Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers , solid tumors , and X-linked severe combined immunodeficiency (X-SCID) .[4] [5] [6]
History
Mustang Bio was founded in 2015 and in the same year became a partner company of Fortress Biotech .[5] [7] In April 2017, Manuel Litchman took over as CEO of Mustang Bio, and in October of the same year, the company signed a lease with the University of Massachusetts Medicine Science Park in Worcester, MA , for a manufacturing facility to support the clinical development and commercialization of CAR-T products for glioblastoma and acute myeloid leukemia .[3] [6] [8] [9]
Until 2018, the company's studies focused mainly on cancer-fighting therapies and cell therapies .[6] After licensing a gene therapy for X-SCID from St Jude Children's Research Hospital , Mustang Bio expanded its efforts to immunodeficiency treatments.[4] [5] In April 2019, it was announced that the gene therapy developed by St. Jude's showed positive results in a trial involving eight infants suffering from X-SCID .[5] [6] [10] [11] Mustang Bio expects to fully take over the trial from St Jude by 2020.[5] [7]
In May 2019, Mustang Bio raised $32 million in an underwritten public offering to fund its continued development of products for the treatment of blood cancers , solid tumors , and rare genetic diseases .[12]
Therapies and treatments
Alongside the X-SCID therapy developed in partnership with St Jude (MB-107), Mustang Bio is conducting research and trials on CAR-T therapies for several diseases, including glioblastoma (MB-101, partnered with City of Hope National Medical Center ), acute myeloid leukemia (MB-102, partnered with City of Hope National Medical Center ), and non-Hodgkin lymphoma and chronic lymphocytic leukemia (MB-106, with Fred Hutchinson Cancer Research Center ).[9] [10] [12]
In May 2019, an oncolytic virus licensed from Nationwide Children's Hospital for the treatment of malignant glioma (MB-108) was granted Orphan Drug status by the Food and Drug Administration .[13] Also in May 2019, the company began recruiting patients for a trial at City of Hope for the treatment of patients with multiple myeloma (MB-104).[12]
In August 2019, Mustang Bio entered into a license agreement with CSL Behring for the Cytegrity stable producer cell line.[14]
References
^ "Mustang Bio, Inc. (MBIO) Company Profile & Key Data" . Seeking Alpha . Retrieved 2019-09-25 .
^ "Mustang Bio Competitors, Revenue and Employees - Owler Company Profile" . Owler . Retrieved 2019-09-25 .
^ a b "Bloomberg - profile" . www.bloomberg.com . Retrieved 2019-09-25 .
^ a b "Mustang and the bubble boy bubble" . Evaluate.com . 2019-04-18. Retrieved 2019-09-25 .
^ a b c d e Ashworth, Will (2019-04-23). "Is Mustang Bio the Next Great Biotech Stock?" . InvestorPlace . Retrieved 2019-09-25 .
^ a b c d "Mustang Bio ventures into gene therapy, licensing 'bubble boy disease' treatment from St. Jude" . Endpoints News . Retrieved 2019-09-25 .
^ a b Cortez, Michelle (April 18, 2019). " 'Bubble Boy' Biotech Soars 250 Percent After Cure Announcement" . www.bloomberg.com . Retrieved 2019-09-25 .
^ "Can tiny Mustang Bio compete on the CAR-T front with giants like Novartis and Gilead? Manny Litchman aims to find out" . Endpoints News . Retrieved 2019-09-25 .
^ a b House, Douglas W. (2017-10-30). "Mustang Bio to set up CAR T manufacturing facility in Massachusetts; shares ahead 9%" . Seeking Alpha . Retrieved 2019-09-25 .
^ a b Budwell, George (2019-04-18). "Why Mustang Bio Stock Is On Fire Today" . The Motley Fool . Retrieved 2019-09-25 .
^ Elder, Bryce (April 18, 2019). "Stocks to watch: Unilever, Moneysupermarket, Mustang Bio, Indivior" . Financial Times . Retrieved 2019-09-25 .
^ a b c Taylor, Phil (2019-05-09). "Mustang Bio's first-of-a-kind CAR-T starts trials" . Pharmaphorum . Retrieved 2019-09-25 .
^ "Mustang Bio's brain cancer-targeting gene therapy granted FDA Orphan Drug designation" . www.beckershospitalreview.com . Retrieved 2019-09-25 .
^ "Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy" . CTIC Capital . Retrieved 2020-04-09 .